364 related articles for article (PubMed ID: 26920690)
1. Glutamatergic NMDA Receptor as Therapeutic Target for Depression.
Réus GZ; Abelaira HM; Tuon T; Titus SE; Ignácio ZM; Rodrigues AL; Quevedo J
Adv Protein Chem Struct Biol; 2016; 103():169-202. PubMed ID: 26920690
[TBL] [Abstract][Full Text] [Related]
2. The role of glutamate on the action of antidepressants.
Hashimoto K
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of glutamate in the pathophysiology of major depressive disorder.
Hashimoto K
Brain Res Rev; 2009 Oct; 61(2):105-23. PubMed ID: 19481572
[TBL] [Abstract][Full Text] [Related]
4. The role of NMDA receptors in the pathophysiology and treatment of mood disorders.
Ghasemi M; Phillips C; Trillo L; De Miguel Z; Das D; Salehi A
Neurosci Biobehav Rev; 2014 Nov; 47():336-58. PubMed ID: 25218759
[TBL] [Abstract][Full Text] [Related]
5. The "blue" side of glutamatergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression.
Szakacs R; Janka Z; Kalman J
Neuropsychopharmacol Hung; 2012 Mar; 14(1):29-40. PubMed ID: 22427468
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression.
Serafini G; Pompili M; Innamorati M; Dwivedi Y; Brahmachari G; Girardi P
Curr Pharm Des; 2013; 19(10):1898-922. PubMed ID: 23173582
[TBL] [Abstract][Full Text] [Related]
7. Targeting of NMDA receptors in the treatment of major depression.
Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
[TBL] [Abstract][Full Text] [Related]
8. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
Preskorn S; Macaluso M; Mehra DO; Zammit G; Moskal JR; Burch RM;
J Psychiatr Pract; 2015 Mar; 21(2):140-9. PubMed ID: 25782764
[TBL] [Abstract][Full Text] [Related]
9. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.
Mathews DC; Henter ID; Zarate CA
Drugs; 2012 Jul; 72(10):1313-33. PubMed ID: 22731961
[TBL] [Abstract][Full Text] [Related]
10. An update on NMDA antagonists in depression.
Pochwat B; Nowak G; Szewczyk B
Expert Rev Neurother; 2019 Nov; 19(11):1055-1067. PubMed ID: 31328587
[No Abstract] [Full Text] [Related]
11. Roles of glutamate signaling in preclinical and/or mechanistic models of depression.
Tokita K; Yamaji T; Hashimoto K
Pharmacol Biochem Behav; 2012 Feb; 100(4):688-704. PubMed ID: 21536063
[TBL] [Abstract][Full Text] [Related]
12. Ketamine and other potential glutamate antidepressants.
Dutta A; McKie S; Deakin JFW
Psychiatry Res; 2015 Jan; 225(1-2):1-13. PubMed ID: 25467702
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.
Jaso BA; Niciu MJ; Iadarola ND; Lally N; Richards EM; Park M; Ballard ED; Nugent AC; Machado-Vieira R; Zarate CA
Curr Neuropharmacol; 2017; 15(1):57-70. PubMed ID: 26997505
[TBL] [Abstract][Full Text] [Related]
14. A brief history of the development of antidepressant drugs: from monoamines to glutamate.
Hillhouse TM; Porter JH
Exp Clin Psychopharmacol; 2015 Feb; 23(1):1-21. PubMed ID: 25643025
[TBL] [Abstract][Full Text] [Related]
15. The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research.
Amidfar M; Woelfer M; Réus GZ; Quevedo J; Walter M; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109668. PubMed ID: 31207274
[TBL] [Abstract][Full Text] [Related]
16. Repurposing of Drugs-The Ketamine Story.
Das J
J Med Chem; 2020 Nov; 63(22):13514-13525. PubMed ID: 32915563
[TBL] [Abstract][Full Text] [Related]
17. NMDA antagonists under investigation for the treatment of major depressive disorder.
Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
[TBL] [Abstract][Full Text] [Related]
18. New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.
Huang YJ; Lane HY; Lin CH
Neural Plast; 2017; 2017():4605971. PubMed ID: 28491480
[TBL] [Abstract][Full Text] [Related]
19. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
Gerhard DM; Wohleb ES; Duman RS
Drug Discov Today; 2016 Mar; 21(3):454-64. PubMed ID: 26854424
[TBL] [Abstract][Full Text] [Related]
20. Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.
Drewniany E; Han J; Hancock C; Jones RL; Lim J; Nemat Gorgani N; Sperry JK; Yu HJ; Raffa RB
J Clin Pharm Ther; 2015 Apr; 40(2):125-30. PubMed ID: 25545040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]